RT-PCR for the Detection of SARS-CoV-2

Molecular assays, such as reverse transcription-polymerase chain reaction (RT-PCR), are accurate and sensitive tools for viral infection diagnosis. As a leading CRO company serving both the therapeutic and diagnostic industry, Creative Biolabs always responds quickly to meet the novel requirements of our industrial partners. At this time, we are well-positioned to assist in providing RT-PCR assay development service for detection of SARS-CoV-2, to aid in the reliable diagnosis of suspected cases.

Introduction to SARS-CoV-2

The SARS-CoV-2 is a novel coronavirus that was first discovered in 2019 in Wuhan, China. This new coronavirus belongs to betacoronavirus and is characterized by human-to-human transmission. The genome sequences suggest the presence of a virus closely related to the members of a viral species termed severe acute respiratory syndrome (SARS)-related CoV. The spread of the infection into different regions of China and even different countries has posed a public threat. Combating this new virus and stopping the epidemic is a matter of urgency. To facilitate public health interventions, one of the foremost priorities is a reliable laboratory diagnosis. However, as it is a newly discovered virus, the spectrum of the available diagnostic tools is tight.

RT-PCR Assay for CoV Detection

RT-PCR is a technology combining RNA reverse transcription (RT) with polymerase chain amplification (PCR) of cDNA. It is a commonly used molecular diagnostic tool to detect coronavirus, including SARS-CoV and MERS-CoV, in human clinical specimens. After the outbreak of SARS-CoV-2, the Centers for Disease Control and Prevention (CDC) quickly developed a new laboratory test kit for SARS-CoV-2 detection, which takes advantage of RT-PCR technology. Moreover, a number of companies in the diagnostic industry are developing molecular diagnostic tests and reagents for SARS-CoV-2, most of which are based on RT-PCR technology.

RT-PCR Assay Development Service for SARS-CoV-2 Detection

Creative Biolabs offers custom RT-PCR assay development services for SARS-CoV-2 detection, conducted by our scientific team with a shared scientific background in infectious diseases and molecular technologies. Besides RT-PCR, our expertise also lies in other molecular diagnostic technologies, including real-time reverse transcription PCR (rRT-PCR), reverse transcription loop-mediated isothermal amplification (RT-LAMP), etc. We offer support in assay design and development, verification, validation, and manufacturing. Our expertise guarantees that we achieve the highest performance levels in terms of assay sensitivity, reproducibility, accuracy, inhibitor tolerance, and specificity.

Features of our Service

• Broad expertise in infectious disease and molecular diagnostic tools
• Quick response and efficient communication to fasten the development of reliable diagnostic tests
• Flexible and competent service to fully satisfy customer needs
• High quality backed by experienced scientific teams and state-of-the-art facilities

Please feel free to contact us if you are interested in our services.

References

1. Corman. V. M.; et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020, 25(3): 2000045.
2. Yu, F.; et al. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes and Infection. 2020.

For Research Use Only. We do not provide direct services or products for patients.